Core Viewpoint - WuXi AppTec (02268) experienced a significant stock price increase, reaching a new high of HKD 75.8, with a current rise of 4.97% to HKD 73.9, and a trading volume of HKD 201 million [1] Group 1: Company Announcement - WuXi AppTec announced a subscription agreement with WuXi Biologics on September 3, involving the issuance of 24.13 million new shares, representing approximately 1.96% of the company's total issued share capital as of the last practicable date [1] - Following the completion of the subscription, WuXi Biologics' ownership will increase from 48.81% to 50.74%, while the public shareholders' stake will decrease from 28.76% to 28.21% [1] Group 2: Financial Details - The net proceeds from the subscription are approximately HKD 1.414 billion, which will be used to expand the group's service capabilities and production capacity [1] - About 90% of the proceeds will be allocated to the expansion of production capacity for bioconjugated drugs and related products, while approximately 10% will be used for general working capital needs [1]
港股异动 | 药明合联(02268)涨超7%再创新高 公司敲定认购协议事项 药明生物持股比例将超50%